Author of

• 20039

  +

  Poster Display Session (ID 63)

  • Event: ELCC 2017
  • Type: Poster Display Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1

  • 19827

    +

    52P - Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small cell lung cancer: A retrospective analysis (ID 308)

    12:30 - 13:00  |  Author(s): H. Wang
    • Abstract

    Background:
    Topotecan is currently the only drug approved by US Food and Drug Administration (FDA) for treatment of relapsed small-cell lung cancer (SCLC) patients. We did this study to attempt to investigate whether combined chemotherapy with etoposide, irinotecan plus cisplatin (PEI) was superior to topotecan alone as second-line treatment for sensitive relapsed SCLC patients.
    
    Methods:
    Between January 2009 and November 2015, a total of 82 relapsed SCLC patients were admitted to the affiliated Cancer Hospital of Zhengzhou University in this retrospective analysis. Among them, 44 patients were treated with combined PEI chemotherapy, while 38 patients were treated with topotecan monotherapy. Disease control rates (DCR), progression-free survival (PFS), overall survival (OS) and adverse reaction were recorded.
    
    Results:
    A total of 82 patients were analyzed. The patients treated with combined chemotherapy had longer median overall survival (OS) (16.3 months vs 10.1 months) than those treated with topotecan (P = 0.001), and median progression-free survival (PFS) time was slightly but significantly longer (6.2 months vs 4.1 months), than the topotecan group. Compared with the topotecan group, more common grade 3 or 4 adverse events were recorded for the combination chemotherapy group, including leucopenia, anaemia, thrombocytopenia. Grade 3-4 non-hematological toxicity was not common. When compared with younger patients, combined chemotherapy-treated patients (≥ 68 years of age) experienced higher rates of leucopenia, anemia, thrombocytopenia and fatigue. Serious adverse events were reported in two patients in the topotecan group and seven patients in the combination group. Two treatment-related deaths (one each of pulmonary infection and pneumonitis) occurred in the combination group, one treatment-related death (pneumonitis) occurred in the topotecan group.
    
    Conclusions:
    Combined chemotherapy with etoposide, irinotecan plus cisplatin (PEI) is not inferior to topotecan monotherapy as the second-line treatment.
    
    Clinical trial identification:
    none
    
    Legal entity responsible for the study:
    None
    
    Funding:
    The National Natural Science Foundation of China (No.81272600)
    
    Disclosure:
    The author has declared no conflicts of interest.